Dirk Nagorsen, MD

Dirk Nagorsen, MD, is the Chief Medical Officer of Affini-T Therapeutics. He has more than 20 years of experience in hematology and oncology, both in academia and industry. Previously he was Vice President Early Development and Therapeutic Area Head, Hematology & Oncology Early Development at Amgen, where he oversaw more than 30 oncology programs spanning IND filings through drug approvals, most notably Lumakras®, the first approved KRAS inhibitor. He also served as the Global Development Leader for blinatumomab/Blincyto®, a CD3 bispecific T cell engager targeting CD19, and led his team to secure Amgen’s first breakthrough designation and first accelerated approval in 2014. Before joining Amgen, he served as a Senior Medical Director at Micromet, a German biotech, through its acquisition by Amgen in 2012. Dirk’s groundbreaking research has resulted in over 60 peer-reviewed manuscripts, including papers published in New England Journal of Medicine, Journal of Clinical Oncology and Lancet Oncology.

Dirk earned his medical doctorate and his habilitation (second scientific degree, equivalent of a PhD) in experimental medicine and tumor immunology from Charité University Medicine Berlin. He trained in internal medicine, hematology,and oncology at the Free University Berlin Medical School, at the NIH Clinical Center Bethesda, Maryland, and at Charité University Medicine Berlin.